Clinical trial
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving…
NCT00317941 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00317941 |
|---|---|
| Title | Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif |
| Official title | The AVANTAGE Study - A Randomized, Multicenter, Phase IV, Open-label Prospective Study Comparing Injection Site Reaction and Injection Site Pain in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) or After a First Demyelinating Event Suggestive of MS Newly Started on Interferon Beta-1b… |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Relapsing-remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Betaferon/Betaseron, Rebif |
| Enrollment | 220 |
| Start date | Mar 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Apr 25, 2006 |
| Last update posted | Oct 21, 2013 |
| Countries | France |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: